A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, New York.

Mike Segar | Reuters

Regeneron Prescribed drugs claimed on Tuesday the U.S. authorities has granted the drugmaker a $450 million agreement to make and supply its double-antibody cocktail that is getting analyzed in opposition to Covid-19.

The antiviral cocktail, REGN-COV2, is in different medical trials equally for dealing with and preventing COVID-19, the business explained.

Supply hyperlink